Neuroregeneration

Nerve Repair Biomaterial Market to Witness Speedy Development Owing to Greater Frequency of Neurological Complaints and Nerve Injuries by 2028: Radiant Insights, Inc.

Retrieved on: 
Wednesday, March 11, 2020
Organ systems, Nervous system, Branches of biology, Neurophysiology, Neuroregeneration, Nerve

The global Nerve Repair Biomaterial Market is witnessing speedy development owing to greater frequency of neurological complaints & nerve injuries, growing elderly residents, augmented finance by the government, and advantageous strategies for compensation.

Key Points: 
  • The global Nerve Repair Biomaterial Market is witnessing speedy development owing to greater frequency of neurological complaints & nerve injuries, growing elderly residents, augmented finance by the government, and advantageous strategies for compensation.
  • The global Nerve Repair Biomaterial Market can be classified by End Users, Type of Injury, Nerve Protection, and Type of Product.
  • By Type of Injury, it can be classified as Group Fascicular Repair, Epineural Nerve Repair, Perineural Nerve Repair.
  • It covers the sales volume, price, revenue, gross margin, historical growth and future perspectives in the Nerve Repair Biomaterial market.

Nerve Repair Biomaterial Market to Witness Speedy Development Owing to Greater Frequency of Neurological Complaints and Nerve Injuries by 2028: Radiant Insights, Inc.

Retrieved on: 
Wednesday, March 11, 2020
Organ systems, Nervous system, Branches of biology, Neurophysiology, Neuroregeneration, Nerve

The global Nerve Repair Biomaterial Market is witnessing speedy development owing to greater frequency of neurological complaints & nerve injuries, growing elderly residents, augmented finance by the government, and advantageous strategies for compensation.

Key Points: 
  • The global Nerve Repair Biomaterial Market is witnessing speedy development owing to greater frequency of neurological complaints & nerve injuries, growing elderly residents, augmented finance by the government, and advantageous strategies for compensation.
  • The global Nerve Repair Biomaterial Market can be classified by End Users, Type of Injury, Nerve Protection, and Type of Product.
  • By Type of Injury, it can be classified as Group Fascicular Repair, Epineural Nerve Repair, Perineural Nerve Repair.
  • It covers the sales volume, price, revenue, gross margin, historical growth and future perspectives in the Nerve Repair Biomaterial market.

Axogen, Inc. to Participate at Upcoming Investor Conferences

Retrieved on: 
Monday, March 2, 2020
Nervous system, Organ systems, Branches of biology, Neurophysiology, Communication, Forward-looking statement, Barclays, Neuroregeneration, Nerve

Karen Zaderej, chairman, CEO, and president will present at the Barclays Global Healthcare Conference in Miami.

Key Points: 
  • Karen Zaderej, chairman, CEO, and president will present at the Barclays Global Healthcare Conference in Miami.
  • The presentation will be webcast live and can be accessed through the Investors page at www.axogeninc.com.
  • Axogen (AXGN) is the leading company focused specifically on the science, development and commercialization of technologies for peripheral nerve regeneration and repair.
  • Forward-looking statements are not a guarantee of future performance, and actual results may differ materially from those projected.

Pipeline Therapeutics to Participate in the SVB Leerink 9th Annual Global Healthcare Conference

Retrieved on: 
Wednesday, February 19, 2020
Biotechnology, Pharmaceutical, Health, Neurophysiology, Neuroregeneration, SVB Leerink, Remyelination, Axon, Biology, Companies, Economy of the United States

Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, today announced that the company will participate in the SVB Leerink 9th Annual Global Healthcare Conference, taking place February 25-27, 2020, in New York, NY.

Key Points: 
  • Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, today announced that the company will participate in the SVB Leerink 9th Annual Global Healthcare Conference, taking place February 25-27, 2020, in New York, NY.
  • Pipeline Therapeutics is a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, including synaptogenesis, remyelination and axonal repair.
  • The companys lead product candidate, PIPE-505, is a small molecule gamma secretase inhibitor (GSI) to treat mild-to-moderate sensorineural hearing loss (SNHL) associated with cochlear synaptopathy.
  • The company also has a portfolio of programs, including PIPE-307, focused on remyelination and axonal repair, to address a range of neurological disorders, including multiple sclerosis.

Axogen, Inc. to Present at the Leerink Partners 9th Annual Global Healthcare Conference

Retrieved on: 
Wednesday, February 5, 2020
Nervous system, Organ systems, Branches of biology, Neurophysiology, SVB Leerink, Neuroregeneration, AxoGen, Nerve

ALACHUA, Fla., Feb. 05, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced that Karen Zaderej, chairman, CEO, and president, will present at the Leerink Partners 9th Annual Global Healthcare Conference in New York City.

Key Points: 
  • ALACHUA, Fla., Feb. 05, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced that Karen Zaderej, chairman, CEO, and president, will present at the Leerink Partners 9th Annual Global Healthcare Conference in New York City.
  • The presentation will be webcast live and can be accessed through the Investors page at www.axogeninc.com .
  • Axogen (AXGN) is the leading company focused specifically on the science, development and commercialization of technologies for peripheral nerve regeneration and repair.
  • The Axogen portfolio of products is available in the United States, Canada, the United Kingdom, and several other European and international countries.

MicroCures Announces Issuance of New Patent Covering First-of-its-Kind Cell Movement Decelerator Technology with Potential Applications in Oncology and Fibrosis

Retrieved on: 
Tuesday, January 14, 2020
Neurophysiology, Neuroregeneration, Tissue engineering, Stem cells

The companys decelerator technology is being developed alongside MicroCures accelerator technology, which is designed to enhance recovery after trauma.

Key Points: 
  • The companys decelerator technology is being developed alongside MicroCures accelerator technology, which is designed to enhance recovery after trauma.
  • MicroCures technology is based on foundational scientific research at Albert Einstein College of Medicine.
  • The company has shown that complex and dynamic networks of microtubules within cells crucially control cell migration, and that this cell movement can be reliably modulated to achieve a range of therapeutic benefits.
  • Additional applications for the companys cell migration accelerator technology include dermal burn repair, corneal burn repair, cavernous nerve regeneration, spinal cord regeneration, and cardiac tissue repair.

Axogen Sponsored RANGER® Registry Reaches 2,000 Nerve Repair Enrollment Milestone

Retrieved on: 
Wednesday, January 8, 2020
Organ systems, Nervous system, Branches of biology, Nerve allograft, Neurosurgery, Neurophysiology, Neuroregeneration, Nerve injury, Nerve, AxoGen

RANGER is the largest multi-center clinical registry in peripheral nerve repair.

Key Points: 
  • RANGER is the largest multi-center clinical registry in peripheral nerve repair.
  • We are pleased with the depth and breadth of nerve repair clinical data that is developing from our RANGER registry, said Karen Zaderej, chairman, CEO, and president.
  • The RANGER registry continues to provide significant new clinical evidence in the management of nerve injuries demonstrating meaningful recovery treating a variety of nerve injuries and gap lengths with Avance Nerve Graft.
  • The RANGER registry, a multicenter Registry of Avance Nerve Graft's Utilization and Recovery Outcomes Post Peripheral Nerve Reconstruction, is an active, multicenter clinical registry designed to continuously monitor and collect injury, repair, safety, and outcomes data for peripheral nerve injuries repaired with processed nerve allograft (Avance Nerve Graft), nerve autograft, and manufactured conduits.

MicroCures Awarded $1.5M SBIR Grant To Support Development of Novel Therapeutic Platform for Accelerated Tissue Repair

Retrieved on: 
Tuesday, January 7, 2020
Organ systems, Nervous system, Branches of biology, Biomedical engineering, Tissue engineering, Neuroregeneration, Nerve

This Phase 2 grant continues the companys successful Phase 1 SBIR contract which demonstrated significantly improved repair of burn wounds following treatment with siFi2 in animal models.

Key Points: 
  • This Phase 2 grant continues the companys successful Phase 1 SBIR contract which demonstrated significantly improved repair of burn wounds following treatment with siFi2 in animal models.
  • The company has developed a broad pipeline of therapeutic programs with an initial focus in the area of tissue, nerve and organ repair.
  • MicroCures has developed a broad pipeline of novel therapeutic programs with an initial focus in the area of tissue, nerve and organ repair.
  • Additional applications for the companys cell migration accelerator technology include dermal burn repair, corneal burn repair, cavernous nerve regeneration, spinal cord regeneration, and cardiac tissue repair.

Axogen, Inc. to Participate at JP Morgan 38th Annual Healthcare Conference

Retrieved on: 
Thursday, January 2, 2020
Branches of biology, Nervous system, Organ systems, Neurophysiology, AxoGen, Neuroregeneration, Nerve, Peripheral nervous system

ALACHUA, Fla., Jan. 02, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced that Karen Zaderej, chairman, CEO, and president, will present at the JP Morgan 38th Annual Healthcare Conference in San Francisco.

Key Points: 
  • ALACHUA, Fla., Jan. 02, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced that Karen Zaderej, chairman, CEO, and president, will present at the JP Morgan 38th Annual Healthcare Conference in San Francisco.
  • The presentation is scheduled for Thursday, January 16, 2020 at 10:30 a.m. PST (1:30 p.m. EST).
  • The presentation will be webcast live and accessible through the Investors page at www.axogeninc.com .
  • Axogen (AXGN) is the leading company focused specifically on the science, development and commercialization of technologies for peripheral nerve regeneration and repair.

Axogen, Inc. to Participate at Piper Jaffray 31st Annual Healthcare Conference

Retrieved on: 
Thursday, November 21, 2019
Nervous system, Organ systems, Branches of biology, Neurophysiology, Neuroregeneration, Piper Jaffray, AxoGen, Nerve

ALACHUA, Fla., Nov. 21, 2019 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced that Karen Zaderej, chairman, CEO, and president, will present at the Piper Jaffray 31st Annual Healthcare Conference in New York City.

Key Points: 
  • ALACHUA, Fla., Nov. 21, 2019 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced that Karen Zaderej, chairman, CEO, and president, will present at the Piper Jaffray 31st Annual Healthcare Conference in New York City.
  • The presentation will be webcast live and accessible through the Investors page at www.axogeninc.com.
  • Axogen (AXGN) is the leading company focused specifically on the science, development and commercialization of technologies for peripheral nerve regeneration and repair.
  • The Axogen portfolio of products is available in the United States, Canada, the United Kingdom, and several other European and international countries.